In this Phase 1 study, we investigated the combination of the MEK inhibitor PD-0325901 with the pan-HER inhibitor dacomitinib in patients with KRASm NSCLC, CRC and pancreatic cancer. Here, MAP2K7 is linked to colorectal carcinoma.